Clinical Trials Logo

Renal Cell Carcinoma (RCC) clinical trials

View clinical trials related to Renal Cell Carcinoma (RCC).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03634540 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Start date: September 27, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.

NCT ID: NCT03260894 Active, not recruiting - Clinical trials for Renal Cell Carcinoma (RCC)

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Start date: December 7, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.